Inhibikase Therapeutics’ $45 Million Follow-On Public Offering

Martina Bellini North America, North America Legal Chronicle
Tagged:

Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal.Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Martina Bellini

Author: Martina Bellini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here